How Much Does Saxenda Cost in District of Columbia in 2026?

Saxenda Retail Price in the District of Columbia

The manufacturer list price set by Novo Nordisk for brand-name Saxenda is $1,349 per month in 2026, and DC retail pharmacies generally match this figure for uninsured cash-pay customers. Each carton contains five pre-filled 3 mL pens delivering liraglutide at a concentration of 6 mg/mL.

Price variation across District pharmacies is minimal compared to states with larger geographic spread. CVS, Walgreens, and independent pharmacies in Northwest, Northeast, and Southeast DC all price within a narrow band of the list price. Some pharmacy benefit managers negotiate modest discounts, but without insurance or a manufacturer coupon, DC residents should expect the full $1,349 monthly cost.

The FDA-approved prescribing information for Saxenda specifies a five-week dose titration from 0.6 mg to the maintenance dose of 3.0 mg daily. During titration, monthly pen consumption is lower, so the first month of therapy may cost less if the pharmacy dispenses fewer pens. Patients who cannot tolerate the 3.0 mg dose and remain on 2.4 mg will also use fewer pens per month.

Compared to newer GLP-1 receptor agonists like semaglutide (Wegovy), Saxenda's monthly cost is lower. Wegovy carries a list price above $1,300 per month with weekly dosing, while Saxenda requires daily injections but remains in a similar price tier. The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that liraglutide 3.0 mg produced a mean weight loss of 8.0% of body weight at 56 weeks compared with 2.6% for placebo 1. This level of efficacy, while meaningful, is somewhat less than the 14.9% seen with semaglutide 2.4 mg in the STEP-1 trial 2.

DC Medicaid Coverage for Saxenda

District of Columbia Medicaid covers Saxenda with prior authorization. This matters. DC has one of the more favorable Medicaid landscapes for anti-obesity medications compared to many states that exclude GLP-1 agonists from their preferred drug lists entirely.

To obtain prior authorization, prescribers typically must document that the patient has a BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia). The prescriber also needs to show that the patient has attempted lifestyle modification, including dietary counseling and increased physical activity, for a defined period, usually 3 to 6 months.

The American Association of Clinical Endocrinology (AACE) 2023 guidelines recommend pharmacotherapy as an adjunct to lifestyle intervention for patients with a BMI ≥27 and obesity-related complications 3. DC Medicaid's coverage criteria broadly align with these recommendations, though the prior authorization process can take 5 to 14 business days. Prescribers in the District should submit the PA request electronically through the DC Medicaid portal and include recent lab work (fasting glucose, HbA1c, lipid panel) along with documentation of prior weight-management efforts.

The DC Department of Health Care Finance (DHCF) administers the District's Medicaid program. Patients denied coverage have the right to appeal, and success rates on appeal are reasonable when clinical documentation is thorough. A 2022 analysis of Medicaid anti-obesity medication coverage across all 50 states and DC found that only 16 state Medicaid programs covered liraglutide 3 mg at that time 4, placing DC in a relatively progressive position.

Private Insurance Coverage in DC

Most major commercial plans available through DC Health Link, the District's health insurance marketplace, include some degree of coverage for FDA-approved anti-obesity medications. Coverage varies by plan tier and carrier.

CareFirst BlueCross BlueShield, the dominant carrier in the DC market, covers Saxenda on select plans with prior authorization and step therapy requirements. Kaiser Permanente Mid-Atlantic also covers Saxenda for qualifying members. United Healthcare and Aetna plans sold in the District may cover Saxenda but often require documentation of failed lifestyle intervention and, in some cases, trial of oral anti-obesity agents like phentermine or orlistat before approving an injectable GLP-1 agonist.

Patients with employer-sponsored insurance should call the number on the back of their pharmacy benefit card to verify coverage before filling a Saxenda prescription. Tier placement matters: Saxenda on a specialty tier (Tier 4 or 5) could carry coinsurance of 25% to 40%, translating to $337 to $540 per month out of pocket even with coverage in place. On a preferred brand tier (Tier 2 or 3), copays typically range from $50 to $150 per fill.

The Consolidated Appropriations Act of 2023 strengthened parity requirements for prescription drug coverage, but anti-obesity medications remain excluded from many employer plans under a longstanding carve-out. The Treat and Reduce Obesity Act (TRAOA), reintroduced in Congress in 2024, would require Medicare Part D coverage of anti-obesity medications and could influence commercial plan design if enacted 5.

Novo Nordisk Savings Card and Discount Programs

The Novo Nordisk Saxenda Savings Card is the single most effective tool for reducing out-of-pocket cost for commercially insured DC residents. Eligible patients may pay as little as $25 per 30-day fill, with Novo Nordisk covering the remainder up to a maximum annual benefit.

Eligibility requirements are straightforward. The patient must have commercial insurance (not Medicare, Medicaid, Tricare, or other government-funded plans), a valid prescription for Saxenda, and U.S. residency. Patients can enroll online through Novo Nordisk's patient assistance portal or receive a card from their prescribing clinician.

For uninsured patients or those whose insurance does not cover Saxenda at all, the savings card benefit is different and typically less generous. Uninsured patients may still receive a discount, but the monthly out-of-pocket cost often remains above $200. Novo Nordisk also operates a Patient Assistance Program (PAP) for patients who meet income criteria, generally at or below 400% of the federal poverty level. In 2026, this threshold is approximately $62,400 for a single-person household. Approved PAP patients receive Saxenda at no cost.

GoodRx, RxSaver, and similar coupon aggregators may reduce cash-pay prices by $50 to $150 at select DC pharmacies. These coupons cannot be combined with insurance or the manufacturer savings card, so they are most useful for cash-pay patients who do not qualify for the PAP.

Compounded Liraglutide 3 mg in the District of Columbia

Compounded liraglutide 3 mg is available in DC through licensed 503A compounding pharmacies. These pharmacies operate under section 503A of the Federal Food, Drug, and Cosmetic Act, which permits compounding of FDA-approved drugs based on individual patient prescriptions 6.

The cost of compounded liraglutide is substantially lower than brand-name Saxenda. Some 503A pharmacies price compounded liraglutide at a fraction of the brand cost, and certain telehealth-integrated compounding pharmacies have offered liraglutide at minimal out-of-pocket expense as part of subscription-based weight management programs. Prices vary by pharmacy and formulation.

Several legal and clinical considerations apply. Compounded drugs are not FDA-approved products, meaning they have not undergone the same manufacturing quality controls, stability testing, or bioequivalence evaluation as brand-name Saxenda. The FDA has issued guidance distinguishing 503A (patient-specific) from 503B (outsourcing facility) compounding, and patients should confirm that their compounding pharmacy holds proper DC Board of Pharmacy licensure.

Dr. Caroline Apovian, a professor at Harvard Medical School and co-author of the Endocrine Society's clinical practice guideline on obesity pharmacotherapy, has noted: "Patients choosing compounded GLP-1 receptor agonists should understand that potency, sterility, and stability may differ from the brand product. The safest approach remains using FDA-approved formulations whenever access and cost allow" 7.

DC residents considering compounded liraglutide should verify that the prescribing clinician is familiar with the specific compounding pharmacy's formulation, concentration, and storage requirements. Dose conversion errors between brand Saxenda pens (6 mg/mL in multi-dose pens) and compounded vials (which may come in different concentrations) are a documented risk.

Telehealth Access to Saxenda in DC

Telehealth prescribing of Saxenda is permitted in the District of Columbia. DC's telehealth parity law, updated in 2021, requires insurers to cover telehealth services at the same rate as in-person visits, removing a previous barrier to virtual obesity medicine consultations.

Several national telehealth platforms, including Ro, Calibrate, and Found, prescribe Saxenda to DC residents. HealthRX also offers telehealth consultations for GLP-1 receptor agonist prescriptions. The virtual visit typically includes a medical history review, BMI calculation, discussion of weight-management goals, and a review of contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or pregnancy) 8.

After a telehealth consultation, the prescriber sends the Saxenda prescription electronically to the patient's preferred DC pharmacy or to a mail-order pharmacy. Mail-order pharmacies may offer modest savings (typically 5% to 10%) over retail for 90-day supplies, and delivery within DC is generally next-day or same-day.

One practical advantage of telehealth for DC residents is scheduling flexibility. Weight-management visits at DC's brick-and-mortar endocrinology and obesity medicine practices often have wait times of 4 to 8 weeks for new patients. Telehealth platforms can frequently schedule initial consultations within 48 hours.

How to Lower Your Saxenda Cost: A Step-by-Step Approach

Reducing out-of-pocket Saxenda expense in DC requires a systematic approach. Start with insurance verification.

First, confirm whether your plan covers Saxenda by calling your pharmacy benefit manager. Request the specific prior authorization criteria so your prescriber can tailor the documentation. Second, if commercially insured, enroll in the Novo Nordisk Savings Card before your first fill. Third, if your insurance denies coverage, file an appeal. Include your prescriber's letter of medical necessity, relevant lab values, and documentation of prior lifestyle intervention. The AACE and Endocrine Society guidelines support pharmacotherapy for patients meeting BMI thresholds 3, and citing these guidelines in the appeal strengthens the case.

Fourth, if you remain uninsured or underinsured after these steps, explore the Novo Nordisk Patient Assistance Program. The application requires proof of income, a valid prescription, and U.S. residency. Fifth, compare prices at DC pharmacies using GoodRx or RxSaver. Price differences of $30 to $100 between pharmacies in the same neighborhood are not unusual. Sixth, ask your prescriber about compounded liraglutide through a licensed 503A pharmacy if brand Saxenda remains unaffordable after all other options.

The SCALE Maintenance trial (N=422) showed that patients who continued liraglutide 3.0 mg after initial weight loss maintained a further 6.2% weight reduction compared with 0.2% in the placebo group over 56 additional weeks 9. This long-term data underscores why sustained access, not just a single month of treatment, matters for clinical outcomes.

Clinical Considerations for DC Prescribers

Prescribers in the District should be aware of several clinical and regulatory points specific to liraglutide 3 mg.

The Saxenda prescribing information includes a boxed warning regarding thyroid C-cell tumors observed in rodent studies. While human relevance remains uncertain, liraglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 8. Prescribers should document thyroid history before initiating therapy.

The 2023 AACE consensus statement recommends GLP-1 receptor agonists as first-line pharmacotherapy for obesity, noting that "the magnitude of weight loss with GLP-1 RAs exceeds that of older agents and approaches levels previously achievable only with bariatric surgery" 3. Liraglutide 3.0 mg occupies a specific niche for patients who prefer a daily injection over weekly dosing (as with semaglutide) or who have tolerability issues with semaglutide's longer half-life.

Common adverse effects in the SCALE trials included nausea (40.2% vs. 14.7% placebo), diarrhea (20.9%), constipation (19.4%), and injection-site reactions 1. Nausea was most common during dose titration and typically resolved by week 8. Prescribers should counsel patients on the titration schedule: 0.6 mg daily for one week, increasing by 0.6 mg weekly until reaching 3.0 mg at week five.

Patients who do not achieve at least 4% weight loss by week 16 on the full 3.0 mg dose are unlikely to reach clinically meaningful weight reduction with continued treatment, and the FDA label recommends discontinuation in these cases.